Roxie Mooney
Board Member @Pneuma Systems Corporation
Signup · Get unlimited contacts
WORK HISTORY
Board Member @Pneuma Systems Corporation
Pneuma Systems is reimagining the infusion therapy landscape with integrated solutions designed to streamline and personalize care for patients managing complex, chronic conditions.As a Board Director, I provide strategic guidance on commercial strategy, investor readiness, and innovation governance as Pneuma prepares for FDA submission and future market entry. Historically, infusion pump technologies have failed to adapt to the clinical complexity and continuum of care required across a patient’s infusion journey. Pneuma is addressing these gaps with a tech-enabled platform designed to modernize intravenous fluid delivery and improve both care coordination and system efficiency.My contributions include: Go-to-market strategy and value proposition development Commercial readiness planning and investor communications Innovation governance and board-level strategic oversightWith a market projected to exceed $31B by 2030, Pneuma is poised to lead a new era in infusion therapy—and I’m honored to help shape that trajectory at the board level.
EDUCATION
Harvard Business School Online
Disruptive Strategy with Clayton Christensen
Rollins College
Bachelor of Arts, Organizational Communication
Palm Beach Atlantic University
Master of Science, Organizational Leadership (MSOL)
Walden University
Doctor of Business Adminstration (DBA), Specialization in Marketing
SKILLS
ABOUT ROXIE MOONEY
I help mid-market healthtech and pharmacy companies increase enterprise value before scale or exit.I work with: CEOs preparing for premium acquisition or institutional scale CMOs under board-level scrutiny for ROI and GTM alignment PE operating partners accelerating portfolio value creationMost companies do not lose valuation during diligence. They lose it earlier through: Fragmented positioning Misaligned GTM systems Founder-dependent narratives Weak proof structuresBuyers form conviction before the process begins.Legacy DNA is a commercialization and valuation partner built specifically for mid-market healthcare complexity.We build: Buyer-ready narratives that transfer beyond the founder GTM systems aligned across brand, demand, and sales Commercialization dashboards boards can defend Proof structures that reduce diligence frictionOur work is grounded in the Commercialization of Innovation framework and 20+ years of healthcare commercialization experience.I’ve helped launch 100+ healthcare innovations and contributed to BioPlus Specialty Pharmacy’s growth from $750M to $2B through two acquisitions.Clarity is a valuation lever.If you are 12–36 months from an exit, preparing for acquisition, or facing sharper board conversations, start with the Exit Readiness Scorecard: https://legacy-dna.com/exit-readiness-scorecardOr Book a strategy call at
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.